Trevi Therapeutics Inc (Nasdaq: TRVI), a US-based clinical-stage biopharmaceutical company, announced on Tuesday that it has named Margaret Garin, MD, MSCR, as its new vice president of Clinical Development.
In the new role, Dr Garin will be responsible for advancing the clinical development of the company's Haduvio in chronic cough.
Dr Garin has more than 14 years of industry and academic research experience and more than nine years of global pharmaceutical industry experience in early and late-stage development. She has served as the executive director of Clinical Development at Bellus Health (now owned by GSK). She was the clinical development lead for programs in respiratory and inflammation at Teva Pharmaceuticals.
Teva's Prolia biosimilar candidate accepted for review by FDA and EMA
Boehringer receives Breakthrough Therapy designation for survodutide
IRLAB Therapeutics reports start of Phase I study for IRL757
GBI Biomanufacturing agrees manufacturing collaboration with Allterum Therapeutics
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Selonterra receives second grant from Michael J Fox Foundation for Parkinson's Research
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
Thermo Fisher Scientific announces expanded biopharma services
GE HealthCare reports promising Phase I results for innovative manganese-based MRI contrast agent
hVIVO reports positive results from RSV antiviral human challenge trial
TiumBio doses first patient in phase two TU2218 clinical trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
ABL Bio signs clinical trial collaboration and supply agreement with MSD